Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ALNY stock, giving a Hold rating on November 25.Don't Miss our ...

Algert Global LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 401.3% ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...

NICE' has said that Wainzua can be used as an alternative to Alnylam's Amvuttra (vutrisiran), which was recommended for NHS ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $310.00.

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s ...